Lumos Pharma, Inc. Stock price

Equities

LUMO

US55028X1090

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
2.64 USD -2.22% Intraday chart for Lumos Pharma, Inc. -13.44% -16.98%
Sales 2024 * 10.51M Sales 2025 * 10.3M Capitalization 21.4M
Net income 2024 * -35M Net income 2025 * -39M EV / Sales 2024 * 2.04 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.08 x
P/E ratio 2024 *
-0.94 x
P/E ratio 2025 *
-1.38 x
Employees 33
Yield 2024 *
-
Yield 2025 *
-
Free-Float 62.88%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.22%
1 week-13.44%
Current month-13.44%
1 month-10.81%
3 months-13.44%
6 months-16.19%
Current year-16.98%
More quotes
1 week
2.51
Extreme 2.5101
3.03
1 month
2.51
Extreme 2.5101
3.12
Current year
2.51
Extreme 2.5101
3.30
1 year
2.51
Extreme 2.5101
4.55
3 years
2.51
Extreme 2.5101
14.46
5 years
2.51
Extreme 2.5101
36.72
10 years
2.51
Extreme 2.5101
36.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 75 10-08-31
Director of Finance/CFO 40 20-02-29
President 59 15-12-31
Members of the board TitleAgeSince
Director/Board Member 64 12-10-31
Chief Executive Officer 75 10-08-31
Director/Board Member 51 13-12-31
More insiders
Date Price Change Volume
24-03-18 2.64 -2.22% 13,189
24-03-15 2.7 +1.89% 33,735
24-03-14 2.65 -10.77% 56,507
24-03-13 2.97 -1.66% 6,657
24-03-12 3.02 -0.98% 36,001

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.64 USD
Average target price
23.33 USD
Spread / Average Target
+783.84%
Consensus
  1. Stock
  2. Equities
  3. Stock Lumos Pharma, Inc. - Nasdaq